

Manual for the laboratory diagnosis of measles and rubella virus infection

Second edition

**The Department of Immunization, Vaccines and Biologicals
thanks the donors whose unspecified financial support
has made the production of this document possible.**

This document was produced by the
Expanded Programme on Immunization (EPI) team
of the Department of Immunization, Vaccines and Biologicals

Ordering code: WHO/IVB/07.01
Printed: August 2007

This publication is available on the Internet at:

www.who.int/vaccines-documents/

**Copies of this document as well additional materials on
immunization, vaccines and biologicals may be requested from:**

World Health Organization
Department of Immunization, Vaccines and Biologicals
CH-1211 Geneva 27, Switzerland

• *Fax:* + 41 22 791 4227 • *Email:* vaccines@who.int •

© World Health Organization 2007

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

Printed by the WHO Document Production Services, Geneva, Switzerland

Contents

| | |
|--|------------|
| <i>Abbreviations and acronyms</i> | <i>vii</i> |
| <i>Acknowledgements</i> | <i>ix</i> |
| 1. Purpose | 1 |
| 2. Introduction | 2 |
| 2.1 Global health burden of measles and rubella | 2 |
| 2.2 Measles | 4 |
| 2.3 Rubella | 9 |
| 2.4 WHO global strategies for measles control and CRS prevention | 15 |
| 3. Role and function of the laboratory in measles control and CRS prevention | 18 |
| 3.1 Role of the laboratory in measles and rubella surveillance | 18 |
| 3.2 Structure and activities of the laboratory network in measles and rubella surveillance | 19 |
| 3.3 Coordination of the network | 22 |
| 3.4 Molecular epidemiology and genotyping | 22 |
| 4. Specimen collection, shipment, receipt and processing | 30 |
| 4.1 Documenting sample collection | 31 |
| 4.2 Serological samples for antibody detection | 31 |
| 4.3 Samples for virus isolation | 35 |
| 4.4 Samples for RT-PCR | 37 |
| 4.5 Alternative sampling techniques (dried blood samples and oral fluid) | 37 |
| 4.6 General safety precautions on receipt of samples | 40 |
| 5. Laboratory diagnosis of measles and rubella | 41 |
| 5.1 IgM assays | 42 |
| 5.2 Tests for IgG antibody | 46 |
| 5.3 RT-PCR | 46 |
| 5.4 Virus isolation in cell culture | 47 |
| 6. Data management and reporting | 49 |
| 6.1 Data management goals | 49 |
| 6.2 Recording receipt of specimen | 52 |
| 6.3 Recording results | 53 |
| 6.4 Reporting laboratory activity and results | 53 |

| | |
|--|------------|
| 7. Safe sample and isolate transport | 55 |
| 7.1 Planning | 55 |
| 7.2 Packaging | 56 |
| 7.3 Preparation and sending | 57 |
| 8. Quality assurance in Network laboratories | 58 |
| 8.1 Establishing LQA systems | 58 |
| 8.2 SOPs | 61 |
| 8.3 Documentation | 62 |
| 8.4 Equipment and instruments | 62 |
| 8.5 Supplies | 63 |
| 8.6 Laboratory safety | 64 |
| 8.7 Annual accreditation | 65 |
| 9. Annexes | 68 |
| 9.1 Example measles and rubella laboratory request form | 69 |
| 9.2 Extraction of measles specific IgM from dried blood specimens and detection for use in the Dade Behring indirect measles IgM antibody assay [After 39] | 70 |
| 9.3 Quality control and trouble shooting of measles and rubella serological assays | 73 |
| 9.4 Isolation and identification of measles and rubella virus in cell culture | 77 |
| 9.5 Packaging of specimens and virus isolates for transportation | 95 |
| 9.6 Composition of media and reagents | 99 |
| 10. Suggested further reading | 101 |
| 10.1 Global impact of measles and rubella | 101 |
| 10.2 Control strategies | 102 |
| 10.3 Laboratory | 103 |
| 10.4 Laboratory safety and sample transport | 104 |
| 11. References | 105 |

List of Figures

| | | |
|------------|---|----|
| Figure 1: | Reported global measles incidence..... | 3 |
| Figure 2: | Clinical features of typical measles - time course from onset of illness | 5 |
| Figure 3: | Immune responses in acute measles infection..... | 6 |
| Figure 4: | Diagram of the measles virus particle correlated with the genetic map | 7 |
| Figure 5: | Clinical features of typical rubella infection - time course from onset of illness | 11 |
| Figure 6: | Immune response in typical rubella infection | 12 |
| Figure 7: | Diagram of the rubella virus particle correlated with the genetic map. The E1 and E2 glycoproteins exist as heterodimers..... | 13 |
| Figure 8: | Countries using rubella vaccine in routine immunization schedules, 2004 | 17 |
| Figure 9: | Laboratory network for measles and rubella surveillance activities at each level | 21 |
| Figure 10: | Global distribution of measles genotypes in WHO regions yet to eliminate measles 1995-2006 | 26 |
| Figure 11: | Global distribution of rubella genotypes 1995-2005 | 29 |
| Figure 12: | Packaging of serum samples. A - individual samples in a sealed bag or pouch. B - multiple samples in an insulated container..... | 34 |
| Figure 13: | Example format for blood spot collection card | 38 |
| Figure 14: | Capture IgM ELISA schematic | 42 |
| Figure 15: | IgM indirect ELISA schematic..... | 43 |
| Figure 16: | Measles/rubella IgM testing strategies under different disease control conditions..... | 44 |
| Figure 17: | Panel A shows cytopathic effect (CPE) caused by measles virus infection of Vero/SLAM cells. Top left panel shows uninfected Vero/SLAM cells; other panels show development of CPE (1+ to 4+ syncytium formation) after infection with wild-type measles virus | 81 |
| Figure 18: | Typical results for detection of rubella virus in cell culture using two different immunoassays: immunofluorescent assay (top row, rubella virus infected and mock-infected) and immunocolorimetric assay (bottom row, rubella virus infected and mock-infected). | 82 |

List of Tables

| | | |
|----------|--|----|
| Table 1: | Sequence of measles virus infection in uncomplicated primary disease | 5 |
| Table 2: | Clinical features of typical rubella infection - time course from onset of illness | 10 |
| Table 3: | Estimated measles deaths and percentage reduction, by geographical region, 1999-2004 | 16 |
| Table 4: | Role of the laboratory in measles and rubella control and elimination | 19 |
| Table 5: | Reference strains to be used for genetic analysis of wild-type measles viruses | 24 |
| Table 6: | Reference strains to be used for genetic analysis of wild-type rubella viruses | 28 |
| Table 7: | Minimum requirements for measles and rubella serology and virus detection according to phase | 30 |
| Table 8: | Density of water at various temperatures and barometric pressures | 76 |

Abbreviations and acronyms

| | |
|-----------------|---|
| µg | microgram |
| µg | microgram |
| µl | microlitre |
| B95a | Epstein-Barr virus-transformed, marmoset B lymphoblastoid cell line |
| BSA | bovine serum albumin |
| BSC | biological safety cabinet |
| BSL | biological safety level |
| CDC | Centers for Disease Control and Prevention, Atlanta USA |
| cDNA | complementary DNA |
| CO ₂ | carbon dioxide |
| CPE | cytopathic effect |
| CRI | congenital rubella infection |
| CRS | congenital rubella syndrome |
| DNA | deoxyribonucleic acid |
| DMEM | Dulbecco's Minimal Essential Medium |
| DMSO | dimethyl sulfoxide |
| EIA | enzyme immunoassay |
| ELISA | enzyme-linked immunosorbent assay |
| EPI | Expanded Programme on Immunization |
| FBS | foetal bovine serum |
| FITC | fluorescein isothiocyanate |
| G | relative centrifugal force |
| g | gram |
| GAVI | Global Alliance for Vaccines and Immunization |
| GSL | Global Specialized Laboratory |
| HPA | Health Protection Agency, London UK |
| IATA | International Air Transport Association |
| ICAO | International Civil Aviation Organization |
| IgA | Immunoglobulin class A |
| IgG | Immunoglobulin class G |
| IgM | Immunoglobulin class M |
| IFA | immunofluorescence assay |
| IVB | Department of Immunization, Vaccines and Biologicals |

| | |
|------------|--|
| kPa | kilopascals |
| LQA | laboratory quality assurance |
| LSM | Lymphocyte Separation Medium |
| MEM | minimal essential medium |
| mg | milligram |
| ml | millilitre |
| MM | maintenance medium |
| MR | measles rubella combination vaccine |
| MMR | measles mumps rubella combination vaccine |
| NL | National Laboratory |
| nm | nanometre |
| OD | optical density |
| PBS | phosphate buffered saline |
| PBMC | peripheral blood mononuclear cells |
| PCR | polymerase chain reaction |
| PT | proficiency test |
| QC | quality control |
| RF | rheumatoid factor |
| RNA | ribonucleic acid |
| RNase | ribonuclease |
| RPM | revolutions per minute |
| RRL | Regional Reference Laboratory |
| RT | reverse transcription |
| RT-PCR | reverse transcription - polymerase chain reaction |
| SIAs | supplemental immunization activities |
| SLAMF | signaling lymphocyte-activation molecule; also known as CDw150 |
| SNL | Sub-National Laboratory |
| SOP | standard operating procedure |
| TMB | 3,3',5,5'-tetramethylbenzidine |
| UNICEF | United Nations Children's Fund |
| V&B | Department of Vaccines and Biologicals (<i>now named IVB, see above</i>) |
| Vero cells | continuous cell line derived from African green monkey kidney |

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_29698

